E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers Tenders > Headlines for 2023 > News item
Published on 2/13/2023 in the Prospect News Liability Management Daily.

GlaxoSmithKline repurchases sterling-denominated notes due 2033, 2039

Chicago, Feb. 13 – GlaxoSmithKline Capital plc repurchased and canceled a portion of the notes of two sterling-denominated series, according to a notice.

The company bought £75.783 million nominal amount of 5.25% notes due Dec. 19, 2033 (ISIN: XS0140516864), leaving £574.166 million notes remaining.

The company also repurchased £68.7 million nominal amount of 6.375% notes due March 9, 2039 (ISIN: XS0350820931), with £631.3 million of the notes outstanding after the repurchase.

The issuer is a multinational pharmaceutical and biotechnology company based in London.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.